Global Orally Disintegrating Tablet Market Worth USD 28.45 Billion by 2033 | CAGR Of 8.11%
Category: HealthcareGlobal Orally Disintegrating Tablet Market Worth USD 28.45 Billion by 2033 | CAGR Of 8.11%
According to a research report published by Spherical Insights & Consulting, the Global Orally Disintegrating Tablet Market Size is Expected to Grow from USD 13.05 billion in 2023 to USD 28.45 billion by 2033, at a CAGR of 8.11% during the forecast period 2023-2033.
Get more details on this report -
Browse key industry insights spread across 217 pages with 120 Market data tables and figures & charts from the report on the "Global Orally Disintegrating Tablet Market Size, Share, and COVID-19 Impact Analysis, By Drug Type (Proton Pump Inhibitors, Anti-Psychotics, Anti-Hypertensives, Anti-Epileptics, and Others), By Indication (GI Diseases, CNS Diseases, CVS Disorders, and Others), By Distribution Channel (Drug Stores, Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/orally-disintegrating-tablet-market
An orally disintegrating tablet market involves the production and distribution of a popular form of pharmaceutical medication used to manage various diseases, particularly those affecting the mouth. These tablets, also known as fast-dissolving, rapimelts, porous tablets, orodispersible tablets, and mouth-dissolving tablets, are formulated using methods like spray drying, mold sublimation, direct compression, freeze-drying, and spray-drying. The market for these tablets is expanding due to the increasing prevalence of deglutition disorders like dysphagia and hypertension in the elderly population. These disorders negatively impact quality of life and work productivity, and the prevalence of hypertension is projected to increase due to the aging population and rising obesity rates. The market for oral disintegrating tablets is expected to grow as more people reach 100 years old. The orally disintegrating tablet (ODT) market is driving due to its convenience, especially for pediatric and geriatric patients, and its quick absorption and recovery process. The trend towards personalized medicine is accelerating the ODT market, with companies investing in research to create customized tablets. ODTs also offer improved patient adherence and longer shelf life. However, the high cost of formulation methods may impede the market growth.
The anti-psychotics segment held the largest share of 38.92% in 2023 and is predicted to grow at a significant CAGR during the predicted period.
Based on the product, the global orally disintegrating tablet market is categorized as proton pump inhibitors, anti-psychotics, anti-hypertensives, anti-epileptics, and others. Among these, the anti-psychotics segment held the largest share of 38.92% in 2023 and is predicted to grow at a significant CAGR during the predicted period. The segment's growth is driven by innovative drug delivery systems, improved efficacy and safety, effective schizophrenia and bipolar disorder treatments, increased research and development, and ease of administration.
The CNS diseases segment accounted for the highest market share of 40.23% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the indication, the global orally disintegrating tablet market is categorized as GI diseases, CNS diseases, CVS disorders, and others. Among these, the CNS diseases segment accounted for the highest market share of 40.23% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segmental expansion is driven by the increasing prevalence of central nervous system diseases, improved patient compliance with ODT formulations, and enhanced therapeutic efficacy.
The hospital pharmacies segment accounted for the highest market share of 28.20% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the distribution channel, the global orally disintegrating tablet market is categorized as drug stores, hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the hospital pharmacies segment accounted for the highest market share of 28.20% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. Hospital pharmacies collaborate to improve patient health outcomes, provide medication compounding and dispensing, ensure regulatory compliance, access patient records, cost-effective drug acquisition, and provide vital consultation services.
North America is expected to hold the greatest share of the global orally disintegrating tablet market over the forecast period.
Get more details on this report -
North America is expected to hold the greatest share of the global orally disintegrating tablet market over the forecast period. North American consumers are increasingly using oral disintegrating tablets (ODTs) due to the rise in chronic diseases like diabetes, heart disease, and central nervous system abnormalities. These tablets dissolve quickly in the mouth, making them useful for travelers. Pharmaceutical firms are investing in advertising and marketing to inform patients and medical professionals about ODTs' benefits. The FDA encourages these businesses to invest in this market, as ODTs offer quicker therapeutic benefits.
Asia Pacific is predicted to hold the fastest-growing region of the global orally disintegrating tablet market throughout the estimated period. The growth of oral disintegrating tablets in Asia Pacific is driven by their cost-effectiveness, increasing awareness among patients and healthcare professionals, and the rising prevalence of chronic diseases due to sedentary lifestyles and secondary factors, contributing to their widespread use.
Major key players in the global orally disintegrating tablet market are Bausch Health, Sun Pharmaceutical Industries Ltd., Merck and Co., Inc., Bayer AG, GlaxoSmithKline plc., Mylan N.V., Johnson & Johnson Services, Inc., Eli Lily Company, Pfizer Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., and others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In January 2025, Sunshine Biopharma, a Canadian pharmaceutical company, launched two new generic prescription drugs, Olanzapine and Olanzapine ODT. Olanzapine, a generic version of Zyprexa, is used for the acute and maintenance treatment of schizophrenia and related psychotic disorders, as well as the acute treatment of manic or mixed episodes of bipolar-I disorder.
- In July 2024, Mind Medicine, a biopharmaceutical company, received a US patent for its proprietary and pharmaceutically optimized form of lysergide (LSD), MM120. MM120 is currently in clinical development for adults with generalized anxiety disorder (GAD) and has the potential to treat other brain health disorders. The patent covers the pharmaceutical formulation, manufacturing methods, and treatment methods for MM120 ODT, which is the first US patent issued on the MM120 ODT formulation. The patent extends MindMed's intellectual property protection for MM120 until 2041.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global orally disintegrating tablet market based on the below-mentioned segments:
Global Orally Disintegrating Tablet Market, By Drug Type
- Proton Pump Inhibitors
- Anti-Psychotics
- Anti-Hypertensives
- Anti-Epileptics
- Others
Global Orally Disintegrating Tablet Market, By Indication
- GI Diseases
- CNS Diseases
- CVS Disorders
- Others
Global Orally Disintegrating Tablet Market, By Distribution Channel
- Drug Stores
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Orally Disintegrating Tablet Market, By Regional
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?